Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.37)
# 329
Out of 4,944 analysts
76
Total ratings
58.49%
Success rate
16.53%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Maintains: Outperform | $30 → $34 | $26.99 | +25.97% | 2 | Aug 12, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $55 | $37.37 | +47.18% | 1 | May 14, 2025 | |
| MRNA Moderna | Maintains: In-Line | $50 → $32 | $26.25 | +21.90% | 6 | May 2, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $190 → $185 | $130.88 | +41.35% | 2 | Apr 24, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $45 → $50 | $51.23 | -2.40% | 3 | Dec 23, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $45 → $50 | $13.74 | +264.03% | 2 | Dec 17, 2024 | |
| BNTX BioNTech SE | Upgrades: Outperform | $110 → $125 | $112.03 | +11.58% | 4 | Nov 19, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $115 → $105 | $57.64 | +82.17% | 12 | Oct 30, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,250 → $1,175 | $567.21 | +107.15% | 5 | Oct 24, 2024 | |
| ACLX Arcellx | Initiates: Outperform | $85 | $70.99 | +19.74% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $28.60 | +207.69% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $133.46 | +106.80% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $3.28 | +967.07% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $289.91 | -19.98% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $85.91 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $119.66 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $28.30 | -25.80% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $5.36 | +329.10% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $10.60 | +2,258.49% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $1.17 | +758.37% | 1 | Feb 14, 2018 |
Summit Therapeutics
Aug 12, 2025
Maintains: Outperform
Price Target: $30 → $34
Current: $26.99
Upside: +25.97%
Xenon Pharmaceuticals
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $37.37
Upside: +47.18%
Moderna
May 2, 2025
Maintains: In-Line
Price Target: $50 → $32
Current: $26.25
Upside: +21.90%
Neurocrine Biosciences
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $130.88
Upside: +41.35%
BridgeBio Pharma
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $51.23
Upside: -2.40%
Edgewise Therapeutics
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $13.74
Upside: +264.03%
BioNTech SE
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $112.03
Upside: +11.58%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $57.64
Upside: +82.17%
Regeneron Pharmaceuticals
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $567.21
Upside: +107.15%
Arcellx
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $70.99
Upside: +19.74%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $28.60
Upside: +207.69%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $133.46
Upside: +106.80%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $3.28
Upside: +967.07%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $289.91
Upside: -19.98%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $85.91
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $119.66
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $28.30
Upside: -25.80%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $5.36
Upside: +329.10%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $10.60
Upside: +2,258.49%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $1.17
Upside: +758.37%